Skip to main content Back to Top
Advertisement

10/15/2020

Cyclopentolate Hydrochloride Ophthalmic Solution

Products Affected - Description

    • Cyclogyl ophthalmic solution, Alcon Labs, 1%, 2 mL bottle, 1 count, NDC 00065-0396-02
    • Cyclogyl ophthalmic solution, Alcon Labs, 1%, 5 mL bottle, 1 count, NDC 00065-0396-05
    • Cyclopentolate hydrochloride ophthalmic solution, Akorn, 0.5%, 15 mL bottle, 1 count, NDC 17478-0096-15
    • Cyclopentolate hydrochloride ophthalmic solution, Akorn, 1%, 15 mL bottle, 1 count, NDC 17478-0100-12
    • Cyclopentolate hydrochloride ophthalmic solution, Akorn, 1%, 2 mL bottle, 1 count, NDC 17478-0100-02
    • Cyclopentolate hydrochloride ophthalmic solution, Akorn, 2%, 15 mL bottle, 1 count, NDC 17478-0097-12
    • Cyclopentolate hydrochloride ophthalmic solution, Akorn, 2%, 2 mL bottle, 1 count, NDC 17478-0097-02
    • Cyclopentolate hydrochloride ophthalmic solution, Akorn, 2%, 5 mL bottle, 1 count, NDC 17478-0097-10
    • Cyclopentolate hydrochloride ophthalmic solution, Bausch Health, 1%, 15 mL bottle, 1 count, NDC 24208-0735-06
    • Cyclopentolate hydrochloride ophthalmic solution, Bausch Health, 1%, 2 mL bottle, 1 count, NDC 24208-0735-01

Reason for the Shortage

    • Akorn did not provide a reason for the shortage.
    • Sandoz has cyclopentolate available.
    • Alcon did not provide a reason for the shortage.
    • Bausch Health did not provide a reason for the shortage.

Available Products

    • Cyclogyl ophthalmic solution, Alcon Labs, 0.5%, 15 mL bottle, 1 count, NDC 00065-0395-15
    • Cyclogyl ophthalmic solution, Alcon Labs, 2%, 15 mL bottle, 1 count, NDC 00065-0397-15
    • Cyclogyl ophthalmic solution, Alcon Labs, 2%, 2 mL bottle, 1 count, NDC 00065-0397-02
    • Cyclogyl ophthalmic solution, Alcon Labs, 2%, 5 mL bottle, 1 count, NDC 00065-0397-05
    • Cyclopentolate hydrochloride ophthalmic solution, Sandoz, 1%, 15 mL bottle, 1 count, NDC 61314-0396-03
    • Cyclopentolate hydrochloride ophthalmic solution, Sandoz, 1%, 2 mL bottle, 1 count, NDC 61314-0396-01

Estimated Resupply Dates

    • Akorn has 0.5% cyclopentolate 15 mL bottles temporarily unavailable. All other presentations are on back order and the company cannot estimate a release date.
    • Alcon has 1% Cyclogyl 2 mL bottles and 5 mL bottles on back order and the company cannot estimate a release date.
    • Bausch Health has 1% cyclopentolate 2 mL and 15 mL bottles on back order and the company estimates a release date of late-October 2020 for the 2 mL bottles and late-December 2020 to early-January 2021 for the 15 mL bottles.

Updated

Updated October 15, 2020 by Leslie Jensen, PharmD, Drug Information Specialist. Created July 9, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.